363 related articles for article (PubMed ID: 11497250)
81. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors.
van Groeningen CJ; Peters GJ; Schornagel JH; Gall H; Noordhuis P; de Vries MJ; Turner SL; Swart MS; Pinedo HM; Hanauske AR; Giaccone G
J Clin Oncol; 2000 Jul; 18(14):2772-9. PubMed ID: 10894878
[TBL] [Abstract][Full Text] [Related]
82. [Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (III)--Teratological study in rabbits by oral administration].
Shinomiya M; Yukiyama S; Ikebuchi K
J Toxicol Sci; 1996 Nov; 21 Suppl 3():619-41. PubMed ID: 9021665
[TBL] [Abstract][Full Text] [Related]
83. Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy.
Kim WY; Nakata B; Hirakawa K
Cancer Sci; 2007 Oct; 98(10):1604-8. PubMed ID: 17683513
[TBL] [Abstract][Full Text] [Related]
84. Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma.
Shirao K; Ohtsu A; Takada H; Mitachi Y; Hirakawa K; Horikoshi N; Okamura T; Hirata K; Saitoh S; Isomoto H; Satoh A
Cancer; 2004 Jun; 100(11):2355-61. PubMed ID: 15160338
[TBL] [Abstract][Full Text] [Related]
85. A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group.
Saek T; Takashima S; Sano M; Horikoshi N; Miura S; Shimizu S; Morimoto K; Kimura M; Aoyama H; Ota J; Noguchi S; Taguchi T
Breast Cancer; 2004; 11(2):194-202. PubMed ID: 15550867
[TBL] [Abstract][Full Text] [Related]
86. [Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (II)--Teratological study in rats by oral administration].
Yukiyama S; Shinomiya M; Ikebuchi K; Sato T
J Toxicol Sci; 1996 Nov; 21 Suppl 3():603-18. PubMed ID: 9021664
[TBL] [Abstract][Full Text] [Related]
87. [Concentration of FT and CDHP and 5-FU in the ascites fluid of patient with peritoneal carcinomatosis after new anti-cancer drug TS-1 oral administration].
Iizuka R; Takahashi S; Kakihara N; Matsumura H; Takenaka A
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1251-3. PubMed ID: 12146009
[No Abstract] [Full Text] [Related]
88. Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) on liver metastasis of xenotransplanted human colon carcinoma.
Konno H; Tanaka T; Baba M; Kanai T; Matsumoto K; Kamiya K; Nakamura S
Jpn J Cancer Res; 1999 Apr; 90(4):448-53. PubMed ID: 10363584
[TBL] [Abstract][Full Text] [Related]
89. Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients.
Zhuang ZX; Zhu H; Wang J; Zhu MG; Wang H; Pu WY; Bian HH; Chen L; Zhang H
Acta Pharmacol Sin; 2013 Apr; 34(4):570-80. PubMed ID: 23396375
[TBL] [Abstract][Full Text] [Related]
90. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo.
Fukushima M; Sakamoto K; Sakata M; Nakagawa F; Saito H; Sakata Y
Oncol Rep; 2010 Nov; 24(5):1307-13. PubMed ID: 20878125
[TBL] [Abstract][Full Text] [Related]
91. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Malet-Martino M; Martino R
Oncologist; 2002; 7(4):288-323. PubMed ID: 12185293
[TBL] [Abstract][Full Text] [Related]
92. Gastrointestinal toxicities of 5-fluorouracil increase the proportion of regulatory T cells in intestinal tract: advantages of alternate-day S-1 administration.
Kajiwara T; Miura K; Ohnuma S; Shimada M; Komura T; Toshima M; Kohyama A; Kudoh K; Haneda S; Musha H; Naitoh T; Shirasaka T; Unno M
Int J Clin Oncol; 2015 Oct; 20(5):913-21. PubMed ID: 25652909
[TBL] [Abstract][Full Text] [Related]
93. [Diamine oxidase as blood biomarker in rats and humans to GI tract toxicity of fluorouracil anti-cancer drugs].
Goto T; Matsubara T; Yoshizawa Y; Sasaya S; Nemoto H; Sanada Y; Moriyama K; Kouchi Y
Gan To Kagaku Ryoho; 2011 May; 38(5):765-9. PubMed ID: 21566434
[TBL] [Abstract][Full Text] [Related]
94. [Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (IV)--Perinatal and postnatal study in rats by oral administration].
Furuhashi T; Kato M; Fujimura T; Koida M
J Toxicol Sci; 1996 Nov; 21 Suppl 3():643-59. PubMed ID: 9021666
[TBL] [Abstract][Full Text] [Related]
95. Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents.
Fukushima M; Iizuka K; Jin C; Zhang C; Hong M; Eshima K
Drug Des Devel Ther; 2017; 11():1693-1705. PubMed ID: 28652707
[TBL] [Abstract][Full Text] [Related]
96. Complete response of a gastric primary after a short but toxic course of 'S-1' EORTC Early Clinical Studies Group.
Schöffski P; Chollet P; Ganser A; Wiese KH; Rambusch E; de Vries MJ; Hanauske A
Ann Oncol; 1999 Sep; 10(9):1117-20. PubMed ID: 10572613
[TBL] [Abstract][Full Text] [Related]
97. Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypridine-1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells.
Nishimura G; Yanoma S; Mizuno H; Satake K; Taguchi T; Ikeda Y; Tsukuda M
Cancer Lett; 2000 Oct; 159(1):1-7. PubMed ID: 10974399
[TBL] [Abstract][Full Text] [Related]
98. [Metabolic characteristics and antitumor activity of BOF-A2, a new 5-fluorouracil derivative].
Shirasaka T; Fukushima M; Shimamoto Y; Kimura Y; Ohshimo H; Imaoka T; Kimura A; Utsunomiya T; Fujii S
Gan To Kagaku Ryoho; 1990 May; 17(5):1051-8. PubMed ID: 2334171
[TBL] [Abstract][Full Text] [Related]
99. Differential effects of 5-fluorouracil analogs on humoral and cell-mediated responses in mice: augmentation of delayed hypersensitivity response against picryl chloride by 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD-1), a new anti-tumor drug.
Yamada Y; Miyauchi S; Unemi N
J Clin Lab Immunol; 1980 Nov; 4(3):153-7. PubMed ID: 6451710
[TBL] [Abstract][Full Text] [Related]
100. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Okuda H; Nishiyama T; Ogura K; Nagayama S; Ikeda K; Yamaguchi S; Nakamura Y; Kawaguchi Y; Watabe T
Drug Metab Dispos; 1997 May; 25(5):270-3. PubMed ID: 9152608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
